MANAGEMENT OF HER2-POSITIVE BREAST CANCER
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with.
HER2-TARGETED THERAPIES IN BREAST CANCERBackground: Trastuzumab deruxtecan (T-DXd) currently represents the standard of care for the treatment of patients with metastatic HER2-positive. (HER2+) breast ... Systemic Therapy of HER2-positive Breast Cancer - OncologyPROtreatment options. ? T-D is a HER2-targeted treatment that fills an unmet need in the 2nd line treatment. It is believed to be a therapeutic advancement due ... Treatment duration of trastuzumab in HER2-positive early breast ...Essayez avec l'orthographe
Autres Cours:
